Treatments for autoimmune disease
AssigneeThe Provost, Fellows, Foundation Scholars, and the Other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin
InventorVincent Kelly
Life of this patent
Estimating the term…
Abstract
The invention provides a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis, using a molecule capable of acting as substrate for the queuine-insertase enzyme complex.
Claims20
A method of treating a patient diagnosed with a T cell-mediated autoimmune disease comprising administering to the patient an effective amount of a molecule acting as a substrate for a queuine-insertase enzyme complex thereby treating the T cell-mediated autoimmune disease,
- wherein the molecule is not a substrate for Hypoxanthine-guanine phosphoribo-syltransferase (HPRT) and treating includes one or more of:
- reversing the T cell-mediated autoimmune disease, alleviating the T cell-mediated autoimmune disease, or palliatively treating the T cell-mediated autoimmune disease,
- wherein the T cell-mediated autoimmune disease is selected from a group consisting of:
- multiple sclerosis, rheumatoid arthritis, ulcerative colitis, psoriasis, diabetes, inflammatory bowel disease, and Crohn's disease.
A method comprising contacting a mammalian cell with a molecule acting as a substrate for a queuine-insertase enzyme complex to reduce or inhibit endogenous cellular mechanism(s) in the mammalian cell associated with a T cell-mediated autoimmune disease, wherein the molecule is not a substrate for Hypoxanthine-guanine phosphoribosyltransferase (HPRT),
- wherein the T cell-mediated autoimmune disease is selected from a group consisting of:
- multiple sclerosis, rheumatoid arthritis, ulcerative colitis, psoriasis, diabetes, inflammatory bowel disease, and Crohn's disease.
A method of treating a patient diagnosed with multiple sclerosis, comprising administering to the patient an effective amount of 2-amino-5-(((3-phenylpropyl)amino)methyl)-3,7-dihydro-4H-pyrrolo[2,-3-d]pyrimidin-4-one, wherein treating includes one or more of:
- reversing the multiple sclerosis, alleviating the multiple sclerosis, or palliatively treating the multiple sclerosis.
Dependencies are inferred from the claim text.